EUVIMEDEUVIMED entdecken
Crossref

Association of Argatroban Dose With Coagulation Laboratory Test in Patients on Extracorporeal Membrane Oxygenation: Activated Clotting Time vs Activated Partial Thromboplastin Time

Hyun-Young Ahn, Yuju Jung, Tae Wan Kim, Yang Hyun Cho, Jeong Hoon Yang, Chi Ryang Chung, Myung-Sook Min, Ryoung-Eun Ko iD

Annals of Pharmacotherapy · 2024

DOI: 10.1177/10600280231183510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Hyun-Young Ahn und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Services, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Liver Diseases, Sulfonamides. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: korea medical device development fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Only some studies have directly compared and analyzed the roles of activated partial thromboplastin time (aPTT) and activated clotting time (ACT) in coagulation monitoring during argatroban administration.

Objectives

This study aims to assess the correlation of argatroban dose with ACT and aPTT values and to identify the optimal coagulation test for argatroban dose adjustment.

Methods

We evaluated 55 patients on extracorporeal membrane oxygenation (ECMO) who received argatroban for more than 72 hours. The correlation between argatroban dose and aPTT and ACT values was evaluated. To compare argatroban dose and bleeding events according to liver dysfunction, the patients were divided into 2 groups based on alanine aminotransferase and total bilirubin.

Results

Among the 55 patients, a total of 459 doses and coagulation tests were evaluated. The aPTT and ACT values showed a weak correlation with argatroban dose, with the Pearson correlation coefficients of 0.261 ( P < 0.001) and 0.194 ( P = 0.001), respectively. The agreement between the target 150 to 180 seconds for ACT and 55 to 75 seconds for aPTT was observed in 140 patients (46.1%). Twenty-four patients (43.6%) had liver dysfunction when they started argatroban. The median argatroban dose was lower in the liver dysfunction group than in the control group (0.094 mcg/kg/min vs 0.169 mcg/kg/min, P = 0.020). Difference was not observed between the 2 groups in the amount of red blood cell (0.47 vs 0.43 pack, P = 0.909) and platelet (0.60 vs 0.08 pack, P = 0.079) transfusion per day. Conclusion and Relevance: A weak correlation was observed between argatroban dose and the aPTT and ACT values. However, the agreement between aPTT and ACT was only 46.1% regarding the scope of target range. Further research is necessary to determine how to assess the optimal argatroban dose for patients administered argatroban while undergoing ECMO at the intensive care unit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracorporeal Membrane OxygenationLiver DiseasesSulfonamidesHumansPartial Thromboplastin TimeHeparinAnticoagulantsPipecolic AcidsArginine

Stichwörter der Autor:innen

ECMOanticoagulationargatrobandrug doseheparin

Substanzen

HeparinAnticoagulantsargatrobanPipecolic AcidsArginineSulfonamides

Autor:innen und Institutionen

  • Department of Pharmaceutical Services, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ORCID-Profile: Ryoung-Eun Ko

Förderung

  • korea medical device development fund

Zitieren

APA

Ahn, H. Y., Jung, Y., Kim, T. W., Cho, Y. H., Yang, J. H., Chung, C. R., Min, M. S., & Ko, R. E. (2024). Association of Argatroban Dose With Coagulation Laboratory Test in Patients on Extracorporeal Membrane Oxygenation: Activated Clotting Time vs Activated Partial Thromboplastin Time. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231183510

Vancouver

Ahn HY, Jung Y, Kim TW, Cho YH, Yang JH, Chung CR, et al. Association of Argatroban Dose With Coagulation Laboratory Test in Patients on Extracorporeal Membrane Oxygenation: Activated Clotting Time vs Activated Partial Thromboplastin Time. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231183510

BibTeX
@article{Ahn2024,
  author = {Ahn, Hyun-Young and Jung, Yuju and Kim, Tae Wan and Cho, Yang Hyun and Yang, Jeong Hoon and Chung, Chi Ryang and Min, Myung-Sook and Ko, Ryoung-Eun},
  title = {Association of Argatroban Dose With Coagulation Laboratory Test in Patients on Extracorporeal Membrane Oxygenation: Activated Clotting Time vs Activated Partial Thromboplastin Time},
  journal = {Annals of Pharmacotherapy},
  year = {2024},
  doi = {10.1177/10600280231183510}
}
Kostenlos starten →